TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06160752

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1 Part A - dose escalation TYRA-200 taken once daily by mouth in 28-day cycles
Description: TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Phase 1 Part B - dose expansion TYRA-200 taken once daily by mouth in 28-day cycles
Description: TYRA-200 is an oral, novel potent FGFR 1/2/3 tyrosine kinase inhibitor that targets tumors that contain activating gene alterations of FGFR2.
Study: NCT06227962

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological assesment
Description: Estimated intelligence (subtasks of Wechsler Intelligence Scale for Children - Fifth edition -Dutch version \[WISC-V-NL\] or Wechsler Adult Intelligence Scale - Forth edition - Dutch version \[WAIS-IV-NL\]); Vienna reaction time; Rey auditory verbal learning test; Word fluency; Beery-Buktenica Developmental Test of Visual-Motor Integration, 6th Edition; Test of Everyday Attention for Children (TEA-Ch), subtask Score!/ or Test of Everyday Attention (TEA), subtask Elevator task; Trail making test; Word-color interference test

Intervention type: DIAGNOSTIC_TEST
Intervention: Neuropsychological assesment
Description: Estimated intelligence (subtasks of Wechsler Intelligence Scale for Children - Fifth edition -Dutch version \[WISC-V-NL\] or Wechsler Adult Intelligence Scale - Forth edition - Dutch version \[WAIS-IV-NL\]); Vienna reaction time; Rey auditory verbal learning test; Word fluency; Beery-Buktenica Developmental Test of Visual-Motor Integration, 6th Edition; Test of Everyday Attention for Children (TEA-Ch), subtask Score!/ or Test of Everyday Attention (TEA), subtask Elevator task; Trail making test; Word-color interference test

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychosocial functioning and quality of life (questionnaires)
Description: Anxiety (PROMIS); Depression (PROMIS); Peer-interaction (PROMIS); Perceived neurocognitive functioning (PROMIS); Participation and activity (PAY-CY); Trauma (KJTS/PCL-5); Health related quality of life (PEDSQL)

Intervention type: DIAGNOSTIC_TEST
Intervention: Psychosocial functioning and quality of life (questionnaires)
Description: Anxiety (PROMIS); Depression (PROMIS); Peer-interaction (PROMIS); Perceived neurocognitive functioning (PROMIS); Participation and activity (PAY-CY); Trauma (KJTS/PCL-5); Health related quality of life (PEDSQL)

Intervention type: DIAGNOSTIC_TEST
Intervention: Parental psychosocial functioning (questionnaires)
Description: Anxiety (PROMIS); Depression (PROMIS); Distress Thermometer-Parents (DT-P); Trauma (PCL-5)
Study: NCT04188119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: (Arm A) Avelumab + Proto Pump Inhibitor (PPI)
Study: NCT05120648

Intervention type: BEHAVIORAL
Intervention: Biofeedback
Description: We propose to study whether patients who complete a clinical six-session biofeedback protocol will demonstrate improvements in mental and physical health.

Intervention type: BEHAVIORAL
Intervention: Biofeedback
Description: We propose to study whether patients who complete a clinical six-session biofeedback protocol will demonstrate improvements in mental and physical health.
Study: NCT04188119

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avelumab
Description: (Arm A) Avelumab + Proto Pump Inhibitor (PPI)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin
Description: 300mg tablets

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: 30mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lansoprazole
Description: 30mg
Study: NCT05542914

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: electronic screening and brief intervention.
Description: e-SBIs is an evidence based approach to engage non-treatment-seeking individuals who use substances to reduce use or enter treatment. It consists of completing screening instruments related to substance use and sexual risk behavior and receiving a tablet-based, Motivational Interviewing intervention to help individuals build motivation to reduce their use and plans to achieve their substance use and HIV risk reduction goals.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: electronic screening and brief intervention.
Description: e-SBIs is an evidence based approach to engage non-treatment-seeking individuals who use substances to reduce use or enter treatment. It consists of completing screening instruments related to substance use and sexual risk behavior and receiving a tablet-based, Motivational Interviewing intervention to help individuals build motivation to reduce their use and plans to achieve their substance use and HIV risk reduction goals.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Men's Health Project (MHP)
Description: This intervention will be offered to participants with moderate or greater severity substance use. This is a 4-session Motivational interviewing based intervention that has shown efficacy in prior studies. We are providing this as a possible referral program for study participants (either arm) who are interested in receiving substance abuse intervention.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Men's Health Project (MHP)
Description: This intervention will be offered to participants with moderate or greater severity substance use. This is a 4-session Motivational interviewing based intervention that has shown efficacy in prior studies. We are providing this as a possible referral program for study participants (either arm) who are interested in receiving substance abuse intervention.
Study: NCT04486833

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: quaratusugene ozeplasmid
Description: Quaratusugene ozeplasmid is an experimental non-viral immunogene therapy utilizing the TUSC2 gene, designed to target cancer cells by interrupting cell signaling pathways that allow cancer cells to grow, reestablishing pathways that promote cancer cell death and modulating the immune response against cancer cells.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: osimertinib
Description: Osimertinib is a 3rd generation EGFR tyrosine kinase inhibitor (TKI) oral tablet administered daily, as indicated for treatment of patients with metastatic NSCLC whose tumors have EGFR genetic deletions or mutations.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Platinum-Based Chemotherapy
Description: Cisplatin and carboplatin are intravenously administered platinum agents that are combined with other cytotoxic chemotherapy agents such as pemetrexed.
Study: NCT05626478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dextenza 0.4Mg Ophthalmic Insert
Description: DEXTENZA 0.4Mg Ophthalmic Insert is a corticosteroid (to decrease inflammation) intracanalicular insert placed in the punctum, a natural opening in the eye lid, and into the canaliculus and is designed to deliver dexamethasone to the ocular surface for up to 30 days without preservatives.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisolone Acetate 1% Oph Susp
Description: Prednisolone Acetate 1% is a corticosteroid (to decrease inflammation) and being used as a topical drop after cataract surgery per Standard Of Care.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prolensa 0.07% Ophthalmic Solution
Description: Prolensa 0.07% is a NSAID (to decrease inflammation, swelling and pain) and is being used as a topical drop after cataract surgery per Standard Of Care.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prolensa 0.07% Ophthalmic Solution
Description: Prolensa 0.07% is a NSAID (to decrease inflammation, swelling and pain) and is being used as a topical drop after cataract surgery per Standard Of Care.
Study: NCT05721378

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Permissive Weight Bearing group
Description: The Permissive Weight Bearing (PWB) protocol allows earlier post-operative permissive weight bearing, where progression of weight bearing is guided by the subjective experience (for example: pain, weight bearing tolerance) of the patient and the clinical expertise of the treating physician and therapist. Patients allocated to the PWB protocol start weight bearing after wound healing is achieved (approximately two weeks after the operation). Consequently, patients are stimulated to bear as much weight as tolerated by pain and comfort. Treatment will take place according to the PROMETHEUS protocol (treatment- and evaluation protocol). The protocol contains a number of weight bearing milestones (e.g. walking with two crutches, walking with two canes, walking with one cane and walking without any walking aids). The treating physiotherapist or physician records the dates that these milestones are reached in the study database.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Restricted Weight Bearing group
Description: The Restrictive Weight Bearing (RWB) protocol consists of 8 to 12 weeks of postoperative restricted weight (0-10%) bearing, following the current AO Guidelines (7). After 8 weeks of restricted weight bearing, the weight bearing will be increased with 25% per week for 4 weeks. Every time the patient and the treating physical therapist or physician have contact, the weight bearing advice given to the patient at that point in time is recorded (unloaded; partial weight bearing + clarification; full weight bearing). Also, any additional advice given to the patient is recorded.
Study: NCT05632016

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: erector spinae block (ESP)
Description: the erector spinae plane block will be performed bilaterally using a high-frequency-curved ultrasound transducer (Mindray 35C50EB, China) placed in a longitudinal orientation 3 cm lateral to the spinous process at two different levels, one above the angle of kyphosis at T8- T10 and another below the angle of kyphosis at L3. An 8- cm 22-gauge block needle (EchoStim; Benlan Inc, Oakville, Canada) is inserted in a cephalad-to-caudad direction until the tip lay in the interfascial plane below erector spinae muscle, the block will be performed by injection of 10 mL of bupivacaine at each point.A total volume of 40 ml of diluted bupivacaine with a total dose of 3mg/kg with variable concentrations according to body weight will be given for each patient.
Study: NCT06539520

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aerobic training program
Description: Aerobic training program; on interval moderate mode, 3 session per week, for 16 weeks, along 30-40 minutes, plus 5-10 minutes of warm up and 5 minutes cooling down, with 50-80% of maximal heart rate for each patient based on age. that progress every month by 10% directed by rating of perceived exertion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Selected physical therapy program for post stroke patients
Description: Selected neurorehabilitation for 1 hour session; 3 sessions per week, for 16 weeks. It involves weight shift side to side, reaching toward weak side, shoulder flexion overhead, shoulder external rotation, overhead press, shoulder internal rotation with Thera-band, heel slides, bridging, lying terminal knee extension, toe and heel raises, sensory reeducation exercises, and body awareness therapy.
Study: NCT06023901

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Apical periodontitis
Description: Radiography of the patients were taken. Blood samples were collected from those patient

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Apical periodontitis
Description: Radiography of the patients were taken. Blood samples were collected from those patient
Study: NCT06539520

Intervention type: OTHER
Group type: OTHER
Intervention: Selected physical therapy program for post stroke patients
Description: Selected neurorehabilitation for 1 hour session; 3 sessions per week, for 16 weeks. It involves weight shift side to side, reaching toward weak side, shoulder flexion overhead, shoulder external rotation, overhead press, shoulder internal rotation with Thera-band, heel slides, bridging, lying terminal knee extension, toe and heel raises, sensory reeducation exercises, and body awareness therapy.
Study: NCT03786003

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: VATS
Description: Standard video assisted thoracic surgery, no use of rib-spreader.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Thoracotomy
Description: Standard thoracotomy
Study: NCT04542642

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: reSET-O
Description: reSET-O is an FDA-authorized mobile application treatment for opioid use disorder.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PEAR-008
Description: PEAR-008 is a new, game-based version of reSET-O, a mobile application treatment for opioid use disorder.
Study: NCT05393388

Intervention type: DRUG
Intervention: [18F]AV-1451
Description: \[18F\]AV-1451 has been developed as a positron emitting radiopharmaceutical for in vivo imaging of tau protein aggregates.
Study: NCT04928482

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Backward Walking Training
Description: Participants will receive 27 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Backward Walking Training
Description: Participants will receive 18 sessions of backward walking training. Each session wil consist of 20 minutes of gait training on a treadmill and 20 minutes of gait training over ground.
Study: NCT04522180

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHR-LRX
Description: GHR-LRX was administered by SC injection.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GHR-LRX
Description: GHR-LRX was administered by SC injection.
Study: NCT04989075

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral prophylactic intervention
Description: The oral prophylactic intervention will consist of the provision of specific package including a soft-bristled manual toothbrush, toothpaste, and a kit of calibrated interdental brushes (IDBs)(Curaprox CPS; Curaden) of sizes corresponding to the diameter of their interdental spaces. The participants will be instructed to brush their teeeth twice-daily and to realise a daily interdental brushing until delivery. The instructions for the use of the toothbrush and IDBs comprised verbal instructions supported by practical demonstration. The first use of the material will be conducted under the supervision of a qualified public health professor.
Study: NCT05852054

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: OB Provider Clinical Decision Support (CDS)
Description: When an eligible patients' chart is opened by a provider, the provider will be alerted to counsel patients about future risk for T2D and hypertension and the need to establish a primary care medical home. The alert will include a 'referral' to primary care and a brief guide with 'key points for counseling'. For patients with prior GDM, this will also include an option to order guideline-recommended oral glucose tolerance test (OGTT) with a single click.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education (OB Visit)
Description: A 1-page document will be printed or delivered electronically for eligible patients after every postpartum OB visit during the STEP-UP condition. The document will encourage patients to know the risk and will describe the importance of routine primary care and chronic disease evaluation and management. It will also provide tips for lowering risk through lifestyle changes. Patient materials will be delivered in English or Spanish based on the structured EHR variable for preferred language.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Text messaging
Description: At 3 months postpartum, all eligible patients who have not scheduled a primary care visit will receive a motivational text to prompt scheduling; a second text will be sent for those who still have not made an appointment. Among those who schedule a visit, a reminder text will be sent before the visit. Texts will be in English or Spanish based on patients' preferred language field in the EHR and written at a \<5th grade reading level.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Outreach
Description: Patients who have not scheduled a primary care visit by 4 months postpartum will receive outreach from a trained coordinator who will assist with scheduling and help patients troubleshoot common barriers, such as concerns about transportation or cost.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Primary Care Provider Clinical Decision Support (CDS)
Description: The CDS will notify the provider that the patient had a recent high-risk pregnancy and signal the need to counsel the individual about their future risk for T2D and/or hypertension and the need for ongoing care. A brief guide with 'key points for counseling' described in plain language will be provided. For patients with prior GDM, the CDS will also include an easy to access 'smartset' to order appropriate testing (A1c, FG, or OGTT) based on time since delivery and provider discussions with the patient.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Patient Education (Primary Care Visit)
Description: A 1-page material will again be automatically printed or delivered electronically for eligible patients after their first primary care visit; it will replicate content from prior material provided after the OB visit.
Study: NCT04902222

Intervention type: DRUG
Intervention: Morphine
Description: Administration of 0.1 mg/kg (IBW) intravenous morphine
Study: NCT06492161

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Physical activity measure
Description: After surgery, patients patients will be fitted with GT3X ActiGraph's activity monitor to capture and record continuous physical activity.
Study: NCT06584682

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sub-occipital muscle inhibition technique
Description: Therapist puts finger pads just beneath the superior nuchal line (below the occiput and above the C2 vertebra), and lifts the patient head slightly and apply an anterior force with cephalic traction on cervical spine this area. Then straighten the fingers to press the finger tips into muscle and hold until relaxation(30 sec) and then drop the head into palm in new position, give this technique in 10 rep/2 sets (each set have 5 repetitions).hot packs for 15 minutes prior to session, cervical muscle stretching,cervical mechanical traction for 8-10 minutes, force is applied 1/6th of the patient body weight, for C1-C2 at 0 degree of cervical flexion and for below C2 at 20 degree of cervical spine flexion and cervical muscle METs
Study: NCT05401435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Resting measurement of blood pressure and heart rate
Description: Simultaneous blood pressure and heart rate measurement every morning and evening during the duration of the experiment (28 days).
Study: NCT05779553

Intervention type: DIAGNOSTIC_TEST
Intervention: Tumor Endothelial Marker 1 ( TEM1 ) by ELISA kits
Description: measurement of serum TEM1 in CRC patients, its relation to staging and comparing the diagnostic performance of serum TEM1 with serum CEA and CA19-9 for diagnosis of CRC. and Early detection of CRC patient

Intervention type: DIAGNOSTIC_TEST
Intervention: Tumor Endothelial Marker 1 ( TEM1 ) by ELISA kits
Description: measurement of serum TEM1 in CRC patients, its relation to staging and comparing the diagnostic performance of serum TEM1 with serum CEA and CA19-9 for diagnosis of CRC. and Early detection of CRC patient
Study: NCT06584682

Intervention type: OTHER
Group type: OTHER
Intervention: conventional therapy
Description: stretching of hamstring muscle, METs, sciatic nerve glides, lower limb neurodynamics.
Study: NCT05699369

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital health interventions
Description: Described in arm descriptions.
Study: NCT05646199

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Participants will receive metformin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Semaglutide Injectable Product
Description: Participants in this group will receive injectable Semaglutide
Study: NCT04834778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HC-5404-FU
Description: HC 5404-FU (hemi fumarate salt of HC 5404) is a novel, highly selective, and potent PERK inhibitor. Preclinical pharmacological studies demonstrated high specificity of HC 5404-FU to PERK and decreased viability of tumor cells. HC 5404-FU will be orally administered BID every day with food or within 30 minutes of completing a meal, starting at 25 mg, with doses escalating to 50, 100, 200, 400, 600, and 900 mg BID as safety allows for each 3-week treatment cycle.
Study: NCT06402851

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Anticoagulant Oral
Description: Patients will be anticoagulated following with 30 mg QD edoxaban or adjusted dose warfarin for a target INR 2.0-3.0.
Study: NCT06402851

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulant Oral
Description: Patients will be anticoagulated following with 30 mg QD edoxaban or adjusted dose warfarin for a target INR 2.0-3.0.
Study: NCT04088136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Everyday Metacognitive Memory Intervention
Description: Provides training in use of techniques and procedures to enhance proactive self-regulatory control over everyday memory demands, including strategies for learning information, planning for meeting everyday goals, and monitoring of efficacy of goal pursuit.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Memory Strategy Control Intervention
Description: Trains use of standard mnemonic techniques such as imagery and sentence generation for learning new associations and organizational and distinctiveness-based strategies for learning sets of items (e.g., word lists).
Study: NCT06329674

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJU-A51
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A51R2
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A51R3
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A51R3
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AJU-A51 Placebo
Description: Subjects take the investigational products once a day for 24 weeks.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A51R2 Placebo
Description: Subjects take the investigational products once a day for 24 weeks.